Nat Med

Timing matters: Morning immunochemotherapy boosts survival in lung cancer

February 5, 2026

In the randomized phase 3 LungTIME‑C01 trial (NCT05549037), 210 patients with treatment‑naive stage IIIC–IV nonsmall cell lung cancer (NSCLC) lacking driver mutations received immunochemotherapy either before or after 15:00 during the first four treatment cycles. After 28.7 months’ median follow‑up, median progression‑free survival was 11.3 months in the early time‑of‑day group vs. 5.7 months in the late group (hazard ratio [HR], 0.40; P < 0.001). Median overall survival was 28.0 months vs. 16.8 months, respectively (HR, 0.42; P < 0.001). Safety findings were consistent with known profiles, with no new signals. Early treatment was associated with increased morning circulating CD8+ T cells and a higher activated‑to‑exhausted CD8+ T‑cell ratio.

Clinical takeaway: Consider morning scheduling of immunochemotherapy for eligible patients with advanced NSCLC, in light of these randomized trial data.

Source:

Huang Z, et al. (2026, February 2). Nat Med. Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/41629425/